Topic: FDA Approves EOVIST(R)

Thought it might be of interest to everyone.
Marions

FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Genetic Engineering News (press release) - New Rochelle,NY,USA
Lesions were characterized as one of the following choices: hepatocellular carcinoma, cholangiocarcinoma, metastasis, focal lymphoma, adenoma, focal nodular ...
See all stories on this topic

THIS INFORMATION IS NOT INTENDED NOR IMPLIED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER